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Abstract
Introduction: Previous observations suggest that active systemic juvenile idiopathic arthritis (sJIA) is associated
with a prominent erythropoiesis gene-expression signature. The aim of this study was to determine the association
of this signature with peripheral blood mononuclear cell (PBMC) subpopulations and its specificity for sJIA as
compared with related conditions.
Methods: The 199 patients with JIA (23 sJIA and 176 non-sJIA) and 38 controls were studied. PBMCs were isolated
and analyzed for multiple surface antigens with flow cytometry and for gene-expression profiles. The proportions
of different PBMC subpopulations were compared among sJIA, non-sJIA patients, and controls and subsequently
correlated with the strength of the erythropoiesis signature. Additional gene-expression data from patients with
familial hemophagocytic lymphohistiocytosis (FHLH) and from a published sJIA cohort were analyzed to determine
whether the erythropoiesis signature was present.
Results: Patients with sJIA had significantly increased proportions of immature cell populations, including CD34
+
cells, correlating highly with the strength of the erythropoiesis signature. The erythropoiesis signature strongly
overlapped with the gene-expression pattern in purified immature erythroid precursors. The expansion of immature
cells was most prominently seen in patients with sJIA and anemia, even in the absence of reticulocytosis. Patients
with non-sJIA and anemia did not exhibit the erythropoiesis signature. The erythropoiesis signature was found to
be prominent in patients with FHLH and in a published cohort of patients with active sJIA, but not in patients with
inactive sJIA.
Conclusions: An erythropoiesis signature in active sJIA is associated with the expansion of CD34
+ cells, also is seen
in some patients with FHLH and infection, and may be an indicator of ineffective erythropoiesis and
hemophagocytosis due to hypercytokinemia.
Introduction
Systemic juvenile idiopathic arthritis (sJIA) differs from
other subtypes of JIA (non-sJIA) in many aspects.
Although most JIA subtypes have in common the pre-
sence of chronic arthritis, patients with sJIA often are
first seen with quotidian hectic fevers, an evanescent
rash, serositis, and hepatosplenomegaly [1]. In contrast
to the other JIA subtypes, marked leukocytosis and
thrombocytosis, severe anemia, a marked acute-phase
reaction, and hyperferritinemia are usually observed.
Other findings supporting a different underlying patho-
genic mechanism in sJIA are the absence of reproduci-
ble HLA associations, autoreactive B and T cells, and
autoantibodies. This has led some investigators to postu-
late that sJIA represents an autoinflammatory rather
than an autoimmune condition [2]. Another striking
aspect of sJIA is its strong correlation with the poten-
tially fatal macrophage-activation syndrome (MAS), also
known as reactive hemophagocytic lymphohistiocytosis
(HLH) [3,4]. Whereas MAS was initially considered a
rare complication of sJIA [5], it now has become
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new-onset sJIA may have subclinical hemophagocytosis
[6-8]. MAS shares many features with familial HLH
(FHLH), including clinical and laboratory features, but
also immunologic abnormalities such as natural killer
(NK) cell dysfunction and elevated levels of soluble IL-
2Ra and soluble CD163 [8,9]. Both conditions are char-
acterized by a marked increase in serum ferritin levels
[10,11]. In our experience, about 50% of patients with
new-onset sJIA have elevated serum ferritin levels of >
500 ng/ml [8], which is used as a cut-off in the diagnos-
tic criteria for HLH [12].
Previous studies have shown heterogeneity among
patients with new-onset sJIA with regard to peripheral
blood mononuclear cell (PBMC) gene expression
[13,14]. At least two different subgroups were apparent,
with their gene-expression pattern corresponding to
serum ferritin levels [14]. These two groups are best dis-
tinguished by the presence or absence of an apparent
erythropoiesis gene-expression signature that contains
multiple erythropoiesis-related genes, including those
encoding embryonic hemoglobins that are usually devel-
opmentally silenced; in addition, an “innate immune
response cluster” was overexpressed in sJIA patients
[15]. Although the overexpression of innate immune-
response genes was expected, the presence of an ery-
thropoiesis signature in sJIA was surprising because of
the reticulocytopenia and absence of apparent erythroid
expansion in this condition [16]. Flow cytometry
demonstrated that patients with sJIA, on average, have a




PBMC subpopulations [14], suggesting that a link exists
between these immature cell populations and the char-
acteristic gene-expression signature.
In this article, we demonstrate that a link exists
between the expansion of immature PBMC subpopula-
tions and characteristic gene-expression signatures in
sJIA and that the erythropoiesis signature also is seen in
patients with FHLH and in some patients with systemic
lupus erythematosus (SLE) and bacterial infections.
Materials and methods
Patients
After written informed consent was provided by their
legal guardians, patients were enrolled in an institutional
review board-approved prospective multicenter study of
gene-expression profiling in childhood arthritis. Patients
with physician-diagnosed JIA, based on the 1997 Inter-
national League of Associations for Rheumatology
(ILAR) criteria, were studied before treatment with dis-
ease-modifying antirheumatic drugs (DMARDs). The
199 patients (23 with sJIA and 176 without sJIA) were
included in this analysis, and 59 healthy controls were
also included in the study. Routine laboratory tests, such
as white blood cell count (WBC), hemoglobin level
(Hgb), platelet count (plt), erythrocyte sedimentation
rate (ESR), and C-reactive protein (CRP), were available
for the majority of the 199 patients (WBC, 188 of 199;
Hgb, 188 of 199; plt, 86 of 199; ESR, 167 of 199; and
CRP, 103 of 199) and were obtained either at the time
of sampling or within 4 weeks before sampling; these
data were not available for control samples. The
patients’ characteristics are shown in Table 1. Overall,
flow-cytometry data were available for 38 of 38 controls
(100%) and 149 of 199 JIA patients (75.0%); gene-
expression data were available for 29 of 38 controls
(64%) and 143 of 199 JIA patients (72.0%). Both flow-
cytometry and gene-expression data were available for
29 of 38 controls (76%) and 107 of 199 JIA patients
(54%). For an additional part of the study, gene-expres-
sion data from PBMC samples of 11 patients with active
familial hemophagocytic lymphohistiocytosis (FHLH)
were studied; no further clinical data were available for
this cohort.
Sample collection
Sample collection was performed as described previously
[13,14] at the time of the baseline visit (before the initia-
tion of DMARD therapy). All further analyses (RNA
microarray analysis, flow cytometry, and cytokine mea-
surement) were performed on these samples. In short,
peripheral blood was collected by using acid citrate dex-
trose (ACD) as the anticoagulant. PBMCs were isolated
by Ficoll gradient centrifugation, and RNA was immedi-
ately stabilized in TRIzol Reagent (Invitrogen, Carlsbad,
CA). Aliquots of PBMCs were frozen separately for flow
cytometry. Samples were frozen and stored at 80°C at
the collecting site before shipment to CCHMC on dry
ice.
RNA processing and microarray analysis
RNA was extracted at CCHMC, purified on RNeasy col-
umns, resuspended in water, and stored at -80°C.
Further RNA processing and quality control was per-
formed as described previously [13]. In short, RNA qual-
ity was assessed by using the Agilent 2100 Bioanalyzer
(Agilent Technologies; Palo Alto, CA). RNA, 100 ng,
was labeled by using NuGEN Ovation version 1. RNA
samples were randomized into groups of 11, and a uni-
versal. standard (pooled PBMC RNA from 35 healthy
adult volunteers) was included in each group to measure
batch-to-batch variation. Labeled cDNA was hybridized
to Affymetrix HG U133 Plus 2.0 GeneChips and
scanned with an Agilent G2500A GeneArray scanner.
Data were assessed for quality and then imported into
GeneSpring GX7.3.1 and pre-processed by using robust
multiarray averaging (RMA) followed by normalization
of each probe to the median of all samples.
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address batch-to-batch variations [17]. These GeneChip
data are available through NCBI’s Gene Expression
Omnibus (GEO) [18], series accession GSE21521.
Flow cytometry
After thawing and washing PBMCs in FACS buffer (PBS
with 0.2% BSA), volumes were adjusted to give a con-
centration of 10
7 cells/ml. Cells were then distributed
into eight tubes (tubes 1 to 6: 5 × 10
5 cells each; tubes 7
and 8, 1 × 10
6 cells each). Single-cell suspensions were
stained with monoclonal antibodies from BD Bios-
ciences (San Jose, CA): anti-BDCA4 (blood dendritic cell
antigen 4)-PE, anti-CD3-Per-CP, anti-CD4-APC, anti-
CD8-FITC, anti-CD11c-APC, anti-CD15-PE, anti-CD16-
FITC, anti-CD19-APC, anti-CD25-PE, anti-CD33-APC,
anti-CD34-FITC, anti-CD45-Per-CP, anti-CD56-APC,
anti-CD105-PE, anti-HLA-DR-PE, anti-lineage-cocktail-1
(Lin)-FITC, anti-TCRa/b-FITC, and anti-TCRg/δ-PE
and IgG1 isotype controls. Cells were analyzed in eight
separate tubes: (a) unstained cells, (b) isotype controls,
(c) anti-CD16-FITC, anti CD15-PE, anti-CD3-PerCP,
and anti-CD56-APC; (d) anti-CD8-FITC, anti-CD25-PE,
anti-CD3-PerCP, and anti-CD4-APC; (e) anti-TCRa/
b-FITC, anti-TCRg/δ-PE, anti-CD3-PerCP, and anti-
CD19-APC; (f) anti-CD34-FITC, anti-CD105-PE, anti-
CD45-PerCP, and anti-CD33-APC; (g) anti-Lin-FITC,
anti-HLA-DR-PE, and anti-CD11c-APC; and (h) anti-
Lin-FITC, anti-BDCA4-PE, and anti-CD11c-APC. Cells
were analyzed on a FACSCalibur flow cytometer (BD)
by using CELLQuest software. Cells were restricted to a
live-cell gate by forward and side-scatter parameters,
and cell populations of interest were captured by stan-
dardized polygonal gates. The following PBMC subpo-












































cells), precursor cells (CD34
+,C D 3 4
+CD33non-myelo-
monocytic precursor cells, CD34
+CD33
+ myelomonocy-
tic precursor cells), other cells (CD45
-CD105
+
endothelial cells), and ratios (NK bright-to-dim ratio
and CD4:CD8 ratio).
Cytokine measurements
25 μl of serum from 16 normal controls, 24 enthesitis-
related, six oligoarticular, eight RF
- polyarticular, and
eight systemic JIA patients included in this study was
used to measure cytokines with a multiplex bead-based
assay (LINCOplex Multiplex Human Cytokine Kit; Milli-
pore, Billerica, MA), according to the manufacturer’s
recommendations.
Data analysis
After import into GeneSpring GX 7.3.1 and preproces-
sing as described before, a supervised analysis was per-
formed by using t test or ANOVA (with a Benjamini
Hochberg false-discovery rate of 5%) followed by
Tukey post hoc testing to identify genes with differen-
tial expression between predefined groups, where
appropriate. Hierarchic clustering of samples and gene
lists with the genes selected by supervised analysis was
performed by using Pearson correlation. With Sigma-
Plot 11.0 (SYSTAT Software, San Jose, CA) for the
comparison of PBMC proportions among the different









+ poly Psoriatic All non-
sJIA
sJIA
Total (n) 38 33 8 53 58 15 9 176 23
Flow (n) 38 30 5 41 41 15 8 149 14
Expression (n) 29 29 7 38 47 14 8 143 21
Flow and expression (n) 29 26 4 26 30 14 7 107 12
Age at onset (yr) 10.8
a ± 5.3 12.4 ± 2.5 4.7 ± 4.7 5.5 ± 4.0 8.1 ± 5.0 10.8 ± 3.0 7.5 ± 4.2 8.2 ± 4.8 5.6 ± 5.0
Onset to baseline (mo) N/A 7.1 ± 7.8 5.7 ± 3.3 4.4 ± 3.3 8.1 ± 8.3 5.8 ± 9.3 6.7 ± 7.5 6.4 ± 7.0 3.6 ± 5.9
Female (%) 57.8 15.2 100 67.9 75.9 93.3 66.7 64.2 34.8
WBC in 10
9/L N/A 6.7 ± 2.0 8.2 ± 2.3 9.0 ± 3.0 8.5 ± 3.6 8.0 ± 2.3 7.6 ± 1.0 8.2 ± 3.0 18.1 ± 9.6
b
Hgb in g/dl N/A 13.1 ± 0.9 11.8 ± 0.9 12.2 ± 1.1 12.3 ± 1.1 12.4 ± 1.3 12.5 ± 0.7 12.4 ± 1.1 9.9 ± 1.4
b
Plt in 10
9/L N/A 324 ± 76 368 ± 109 369 ± 96 384 ± 152 375 ± 113 370 ± 96 366 ± 117 548 ± 227
b
ESR in mm/h N/A 15 ± 16 23 ± 17 19 ± 15 23 ± 18 31 ± 24 19 ± 17 21 ± 17 89 ± 40
b
CRP in mg/dl N/A 1.6 ± 2.2 0.9 ± 1.3 1.2 ± 1.4 1.8 ± 2.8 2.0 ± 2.0 1.0 ± 0.9 1.5 ± 2.1 16.9 ± 14.0
b
aAge at sampling.
bP < 0.05 (one-way ANOVA and all multiple pairwise comparisons (Tukey)). Numbers represent mean ± standard deviation, unless otherwise
indicated. WBC, white blood cell count; Hgb, hemoglobin; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
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formed, followed by post hoc multiple pairwise com-
parisons (Tukey), always assuming a significance level
of 0.05. For longitudinal comparisons, paired t tests (if
normally distributed) or signed-rank tests (if not nor-
mally distributed) were performed. For the correlation
analysis between gene-expression signatures and
PBMC subpopulations, Pearson’s correlation coeffi-
cients were determined. As an indicator of the strength
of the expression of the erythropoiesis signature in
individual samples, the geometric mean
( () aa a n
n
12 ×××  ) of the linear expression values of
the 67 probe sets in the erythropoiesis signature was
calculated and termed the erythropoiesis index. Recei-
ver-operating characteristic (ROC) curve analysis was
performed by using SigmaPlot 11.0.
Signature-overlap analysis
A subset of the GeneChip data (721 B-Lymphoblast,
BDCA4
+,C D 1 0 5
+,C D 1 4
+,C D 1 9
+,C D 3 3





+,a n dC D 7 1
+) from a larger data set
[19] was imported into GeneSpring 7.3 with RMA pre-
processing. Because of limited replicates (two for each
cell type), probes sets with a ratio of > 3 (geometric
mean of specific cell type to geometric mean of all cell
types) were considered expressed in a cell type. Different
GeneChips were used for the current analysis (HG U133
plus 2.0) and the imported dataset (HG U133A), and it
was determined that only 49 of the 67 erythropoiesis
probe sets were present on both arrays.
Results
PBMC subpopulations in non-sJIA, sJIA, and controls
In a previous study, by comparing PBMC gene expres-
sion between sJIA patients and healthy controls, we
identified a group of 67 probe sets that we defined as an
erythropoiesis signature [14]. To better understand the
origin of this erythropoiesis signature, PBMC phenotyp-
ing by flow cytometry was performed. For this purpose,
26 PBMC subpopulations or ratios were compared
among the different JIA subtypes. When comparing the
percentages of the different PBMC cell populations
among patients with non-sJIA, sJIA, and controls, 10
subpopulations or ratios had different mean percentages
(ANOVA; P <0 . 0 5 ) :C D 3
-CD56




-,C D 1 9
+,C D 3 4
+,C D 3 4
+CD33





+,C D 5 6
+ bright-to-dim ratio and CD4:CD8
ratio (Table 2). Most of the differences were observed
when comparing the sJIA patients with either (a)
patients with non-sJIA or (b) controls, as shown by
Tukey’sp a i r w i s em u l t i p l ec o m p a r i s o np r o c e d u r e( post
hoc testing). An expansion of the following immature
PBMC subpopulations in the sJIA group was observed




+,C D 3 4
+CD33
-,a n dC D 3 4
+CD33
+
precursor cells. To determine whether the various
immature cell populations across all samples correlate
with each other, we compared the percentages of imma-


















(r =0 . 9 6 ) ,C D 3 4
+ and CD34
+CD33





+ (r = 0.45).
Correlation of an erythropoiesis signature and innate
immune response signature with immature precursor
cells
T h ep r e v i o u s l ym e n t i o n e da n d reported erythropoiesis
signature consists of 67 probe sets, many representing
fetal and embryonic hemoglobins (hemoglobins δ, μ, g,
and θ), erythrocyte structural proteins (erythrocyte
membrane protein band 4.2), surface proteins (glyco-
phorins A, C), transporter proteins (solute carrier
family 22, member 4; solute carrier family 25, member
37), enzymes (2,3-bisphosphoglycerate mutase, carbo-
nic anhydrase I, δ-aminolevulinate synthase 2), and
transcription factors (Kruppel-like factor 1) (see Addi-
tional file 1) [14]. Because this signature could poten-
tially be produced by immature PBMC subpopulations,
such as erythrocyte precursors, we wanted to deter-
mine whether this signature is associated with an
expansion of immature PBMC subpopulations. We
defined the erythropoiesis index as the geometric mean
of the normalized expression values of the 67 probe
sets contained in the erythropoiesis signature, signify-
ing the strength of the erythropoiesis signature in indi-
vidual samples or patients. The erythropoiesis index
correlated significantly with the percentage of imma-




-,a n dC D 1 5
+CD16
-; no significant correla-
tion appeared for other PBMC subpopulations (data
not shown). A similarly large correlation was observed
for a previously described “innate immune response
cluster” [14] with the following cell populations:
CD34
+ (r =0 . 6 4 ) ,C D 3 4
+CD33
- (r = 0.60) and CD15
+CD16
- (r = 0.47), CD34
+CD33
+ (r = 0.46), indicating
that these cells are also highly associated with this
gene-expression signature.
The erythropoiesis signature overlaps with the gene-
expression patterns from purified CD71
+ erythroid
precursors
At the initiation of these studies, we did not anticipate
finding an erythropoiesis signature; therefore, this study
was not designed to measure erythrocyte precursor cells
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observed erythropoiesis signature, we assessed its over-
lap with the gene-expression signatures that we derived
from a publicly available dataset derived from isolated
cell populations [19]. The publicly available dataset was
generated by using Affymetrix U133A microarrays,
whereas our data were generated by using U133 Plus 2.0
GeneChips. Of the 67 probe sets defining the erythro-
poiesis signature, only 49 were present in the U133A
arrays. As shown in Table 4, of the 49 probe sets, 39
(79%) were found in the signature of CD71
+ immature
erythroid precursor cells. A smaller overlap was
observed with CD105
+ mesenchymal stem/endothelial
precursor cells (36.7%), and hematopoietic CD34
+ cells
(8%). In contrast, essentially no overlap was found with
the signatures of BDCA4
+,C D 1 4
+,C D 1 9




+,o rC D 8
+ cells, suggesting that the most
likely origin of the erythropoiesis signature was imma-
ture erythroid precursors. These results were
also investigated through hierarchic clustering (see
Additional file 2).
Expansion of immature CD34
+ cells mainly in sJIA with
anemia
One of the features of sJIA is severe anemia with reti-
culocytopenia [16]; therefore, the presence of an ery-
thropoiesis signature was surprising. Because the
erythropoiesis signature correlated with the PBMC per-




-,C D 3 4
+CD33
+), a further analysis was
performed to determine whether the expansion of
these cell populations is related to the presence or
absence of anemia (hemoglobin < 11 g/dl). For 21
patients with sJIA and for 166 patients with non-sJIA,
hemoglobin levels were available. The groups had the
following characteristics (n; Hgb mean ± standard
deviation; ESR, mean ± standard deviation): (1) sJIA
with anemia (n = 18; Hgb, 9.4 ± 1.0 g/dl; ESR, 96 ± 36
mm/h); (2) sJIA without anemia (n =3 ;H g b ,1 1 . 9±
1.0 g/dl; ESR, 62 ± 49 mm/h); (3) non-sJIA with ane-
mia (n = 21; Hgb, 10.5 ± 0.4 g/dl; ESR, 33 ± 18 mm/
h); and (4) non-sJIA without anemia (n = 145; Hgb,
12.7 ± 0.9 g/dl; ESR, 18 ± 18 mm/h). Patients with
sJIA and anemia had a significantly larger proportion
of circulating CD34
+,C D 3 4
+CD33
-,a n dC D 3 4
+CD33
+
cells than did individuals with non-sJIA with or with-
out anemia (Figure 1a). Although the values did not
reach statistical significance, patients with sJIA and
anemia trended toward higher percentages of CD34
+
cell subpopulations than did patients with sJIA without
anemia, suggesting that the expansion of these imma-
ture PBMC subpopulations was rather specific to
Table 2 PBMC subpopulations for which significant differences existed between the controls, patients with JIA other
than sJIA, and patients with systemic arthritis
PBMC subpopulation Percentage of PBMC Pairwise multiple comparison
1. Controls 2. non-sJIA 3. sJIA ANOVA 1. vs. 2. 1. vs. 3. 2. vs. 3.
CD3
-CD56
+ 6.1 ± 3.9 7.4 ± 4.0 4.7 ± 1.7 0.02 NS NS < 0.05
CD56
+ dim 5.5 ± 3.5 6.7 ± 3.9 3.7 ± 1.4 0.009 NS NS < 0.05
CD15
+CD16
- 0.05 ± 0.03 0.06 ± 0.05 0.18 ± 0.19 < 0.001 NS < 0.05 < 0.05
CD8
+CD25
+ 0.46 ± 0.26 0.78 ± 0.60 0.70 ± 0.40 0.005 < 0.05 NS NS
CD19
+ 16.8 ± 6.6 13.2 ± 5.8 11.7 ± 6.6 0.002 < 0.05 < 0.05 NS
CD34
+ 0.08 ± 0.04 0.08 ± 0.05 0.16 ± 0.11 < 0.001 NS < 0.05 < 0.05
CD34
+CD33
- 0.05 ± 0.03 0.06 ± 0.04 0.11 ± 0.09 < 0.001 NS < 0.05 < 0.05
CD34
+CD33
+ 0.03 ± 0.02 0.02 ± 0.02 0.05 ± 0.03 < 0.001 < 0.05 NS < 0.05
NK bright/dim ratio 0.14 ± 0.09 0.13 ± 0.12 0.28 ± 0.16 < 0.001 NS < 0.05 < 0.05
CD4:CD8 ratio 2.20 ± 0.7 2.14 ± 0.7 2.81 ± 0.9 0.006 NS < 0.05 < 0.05
Differences were analyzed with one-way ANOVA followed by Tukey’s pairwise multiple comparison, assuming a significance level of P < 0.05. PBMCs, peripheral
blood mononuclear cells; JIA, juvenile idiopathic arthritis; sJIA, systemic JIA; non-sJIA, JIA other than sJIA.
Table 3 Pearson correlation coefficients of the geometric
mean of the erythropoiesis gene-expression signature
values and different PBMC subpopulations across all
available samples (n = 152)
PBMC subpopulation/ratio r (Pearson) Correlation P value
CD34
+ 0.48 < 0.001
CD34
+CD33
- 0.45 < 0.001
CD15
+CD16
- 0.45 < 0.001
CD34
+CD33
+ 0.36 < 0.001




|r| > 0.5 represents a large degree of correlation, 0.3 < |r| < 0.5 represents a
moderate degree of correlation and 0.1 < |r| < 0.3 represents a small degree
of correlation; |r| < 0.1 represents a lack of correlation (upper panel). Only
PBMC subpopulations are shown for which P was < 0.05. A low P value
indicates that the observed correlation coefficient is due to a statistically
significant relation between the two variables.
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sis was restricted because of the low number of
patients with sJIA who did not have anemia (n =3 ) .
Evidence for the absence of reticulocytes in the
peripheral blood of patients with systemic arthritis
As mentioned earlier, this study was not designed to
measure directly the erythrocyte precursor cells,
including reticulocytes. Instead, we used the red-cell
distribution width (RDW) as a surrogate marker for
the presence of reticulocytosis, as it is well recognized
that the RDW highly correlates with the reticulocyte
count [20]. These data were available for 12 patients
with sJIA in this study. A significant degree of anemia
at the baseline visit rapidly and significantly improved
after treatment (paired t test; baseline vs. 30 days, P =
0.002; baseline vs. 60 days, P < 0.001; baseline vs. 90
days, P = 0.01; the test results closest to 30, 60, and 90
days, respectively, were used) (Figure 1b). The patients
with sJIA had a normal RDW at the baseline visit
(before receiving any treatment) but experienced a
rapid, and significant, increase in the RDW, suggesting
the development of reticulocytosis, after initiation of
treatment. This decreased at later times (paired t test;
baseline vs. 30 days, P < 0.001; baseline vs. 60 days, P
= 0.02; baseline vs. 90 days, P = 0.11; the test results
closest to 30, 60, and 90 days, respectively, were used)
(Figure 1c). Concurrently, the percentage of circulating
CD34
+ precursor cells also decreased within 6 to 12
months (t test; baseline vs. 6 months, P =0 . 0 4 ;b a s e -
line vs. 12 months, P = 0.02; baseline vs. 24 months,
P = 0.275) (Figure 1d).
Erythropoiesis signature in systemic arthritis with anemia
but not in other JIA subtypes with anemia
Because we identified PBMC subpopulation differences
between patients with or without anemia, and to expand
our analysis, we looked at gene-expression differences
among sJIA and non-sJIA, with and without anemia.
Similarly, when comparing gene expression between
patients with sJIA with anemia and non-sJIA patients
with anemia, 671 genes were differentially expressed (t
test, 5% FDR [see Additional file 3]). With hierarchic
clustering, similar gene clusters emerged, with cluster II
and IV being most coherent and upregulated (Figure
2a). A strong segregation of the sample tree was noted,
with sJIA patients separating from other JIA patients.
Cluster IV (162 genes) corresponded to the previously
observed erythropoiesis expression signature, as it con-
tained 52 of the 67 probe sets contained in the initially
described erythropoiesis signature [14]. No clustering
was observed when comparing patients with sJIA with
anemia with patients with sJIA without anemia. The
strength of the expression of the erythropoiesis signa-
ture in PBMCs was examined in seven patients in
whom longitudinal data were available. A marked and
significant decrease in the erythropoiesis index between
baseline and 12 months later was observed (Figure 1e)
(P = 0.02, Signed Rank test).
Overlap with gene expression in PBMC in FHLH
Given the clinical and laboratory similarities between
sJIA, MAS, and HLH, we attempted to determine
whether a similar erythropoiesis signature was present
in patients with FHLH. PBMC-derived RNAs from 11
Table 4 Overlap between erythropoiesis signature and cell-specific signatures













+ T lymphocytes 211 0 0 0.9%
CD8
+ T lymphocytes 252 0 0 1.1%
CD14
+ monocytes 447 0 0 2.0%
CD19
+ B lymphocytes 272 1 2.0% 1.2%
CD56
+ NK cells 265 0 0 1.2%
CD33
+ myeloid lineage 448 0 0 2.0%
CD34
+ stem cells 227 4 8.2% 1.0%
CD105
+ mesenchymal stem cells/endothelial
precursors
360 18 36.7% 1.6%
CD71
+ erythroid precursors 563 39 79.6% 2.5%
BDCA4
+ dendritic cells 372 0 0 1.7%
aDetermined by using the HG U133A GeneChip.
bNumber relative to the 49 probe sets from the erythropoiesis signature that are present on the U133A GeneChip.
c(Number of probe sets overlapping with erythropoiesis signature)/(49(total of probe sets in the erythropoiesis signature)) × 100.
d(Number of probe sets in the signature) × (49(total of probe sets in the erythropoiesis signature))/(22,283 total of probe sets on the U133A GeneChip) × 100.
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archic clustering of the 67 probes contained in the ery-
thropoiesis signature by using samples from patients
with FHLH, sJIA, sJIA with MAS, and healthy controls
resulted in a partially homogenous cluster with the sJIA
and FHLH samples clustering together (Figure 2b), sug-
gesting activation of similar pathways.
The erythropoiesis signature in other sJIA cohorts
To determine how specific the erythropoiesis signature
was for sJIA, we expanded our analysis to previously
published gene-expression data of a non-overlapping
cohort. Studies by Allantaz et al. [21] examined PBMC
gene expression in patients with active and inactive sJIA
and other diseases, including bacterial infections, sys-
temic lupus erythematosus (SLE), and PAPA syndrome
by using Affymetrix U133A and U133B GeneChips [21].
We used this dataset (accessed via the GEO database;
records GSE8650 and GSE6269) to determine the pre-
sence or absence of the erythropoiesis signature. Of the
67 probe sets, 49 contained in the erythropoiesis signa-
ture (determined on the Affymetrix U133 Plus 2.0
arrays) were also contained on the U133A GeneChip.
We used the modified erythropoiesis index (the geo-
metric mean of the normalized expression values of the
49 probe sets that were available) for further analyses.
Comparing the mean of the erythropoiesis indices
among the different groups showed that the highest
levels of expression of the erythropoiesis signature were
observed in patients with sJIA, with statistically signifi-
cant differences between (a) sJIA and controls, and (b)
sJIA and SLE (Figure 3a). In an effort to understand
which clinical characteristics were relevant for the ery-
throcyte signature, we separated patients based on the
absence or presence of fever, arthritis, and medical
treatment provided in the GEO database. When com-
paring patients with sJIA with fever with patients with
sJIA without fever, and patients with sJIA with arthritis
with patients with sJIA without arthritis, a significantly
increased expression of the erythropoiesis signature in
patients with active sJIA (with fever or arthritis) was
observed (Figure 3b). However, no difference in the
expression of the erythropoiesis signature was found,
whether or not patients were treated with steroids,
methotrexate, or infliximab (Figure 3c). When compar-
ing the erythropoiesis-signature expression across all
groups and subdividing sJIA into those patients with or
without fever, the expression is significantly increased in
patients with active sJIA (with fever) when compared
with controls, other diseases, and inactive sJIA (without
fever) (Figure 3d). To analyze further the discriminating
strength of the erythropoiesis index, we performed ROC
curve analyses. An area under the curve (AUC) of 1
indicates a perfect diagnostic test, whereas an AUC of
Figure 1 Comparison of CD34
+ precursor cell populations and
time course of Hgb, RDW, CD34
+ cell proportions and
erythropoiesis index. (a) Concentration of circulating CD34
+
precursor cells expressed as proportion of PBMCs in patients with
sJIA and other JIA subtypes with or without anemia. *P < 0.05
(Student’s t test). (b) Time course of individual hemoglobin
concentration after the baseline sample and initiation of treatment
in 12 patients with sJIA. A significant increase was noted between
baseline and time points 30, 60, and 90 days (paired t test, P <
0.05). (c) Time course of individual red-cell distribution width (RDW)
after the baseline sample and initiation of treatment in 12 patients
with sJIA. A significant increase was seen between baseline and
time points 30 and 60 days (paired t test, P < 0.05). (d) Decrease in
CD34
+ precursor cell proportions after initiation of treatment in 13
patients with sJIA. A significant decrease was found between
baseline and time points 6 months and 12 months (t test, P < 0.05).
(e) Decrease in the erythropoiesis index (geometric mean of the
erythropoiesis signature expression) between baseline and 12
months later in seven patients for whom longitudinal gene-
expression data were available (Signed-rank test, P < 0.05). sJIA,
systemic juvenile idiopathic arthritis; non-sJIA, JIA other than sJIA;
PBMCs, peripheral blood mononuclear cells; Hgb, hemoglobin; RDW,
red cell distribution width.
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Page 7 of 130.5 indicates a test result no better than chance. The
AUC of the comparison active sJIA (with fever) versus
bacterial infection was 0.82 [see Additional file 4]. The
AUC of the comparison active sJIA (with fever) versus
“inactive” sJIA (no fever) was 0.92 [see Additional file
4]. The large area under the curve indicates that, in this
cohort, the erythropoiesis index was able to discriminate
well between patients with active sJIA and bacterial
infection and even better between patients with active
sJIA and inactive sJIA. Nevertheless, a number of
patients with bacterial infections also had an elevated
erythropoiesis index, again indicating that the signature
was not entirely unique to patients with sJIA.
Erythropoiesis signature and serum cytokines
Because IL-6 has been implicated in the development of
anemia in systemic JIA, we assessed the degree of corre-
lation between the erythropoiesis signature and serum
levels of various cytokines, including IL-6. Serum sam-
ples from 16 normal controls, 24 enthesitis-related, six
oligoarticular, eight polyarticular RF
-,a n de i g h ts J I A
patients were used in this part of the study. As shown
In Figure 4, when all JIA samples were combined, no
moderate or strong correlations were observed. When
patients with sJIA were analyzed separately, we observed
a moderate correlation with IL-17 and IL-10, but only a
mild correlation with IL-6. The eight patients with sJIA
included in this analysis were representative of the
entire sJIA cohort in this study (Hgb mean, 9.5 g/dl;
standard deviation, 1.3; CRP mean, 15.3 mg/dl; standard
deviation, 8.6; ESR mean, 89 mm/h; standard deviation,
51). Serum IL-6 levels in patients with sJIA ranged
between 11.9 and 481.2 pg/ml (mean, 179.4 pg/ml; stan-
dard deviation, 180.1 pg/ml).
Erythroid precursors in the bone marrow of patients with
systemic JIA and anemia
In two of the patients included in this study, bone mar-
row biopsy was performed as a part of the initial diag-
nostic evaluation to rule out malignancy (these patients
had relatively low Hb levels: 7.2 and 7.8 g/dl). Both
patients were found to have hypercellular bone marrow
with mild expansion of erythroid lineage (Figure 5).
These patients also had moderate expansion of CD163
+
histiocytes, a phenomenon viewed by some [7] as early
stages of MAS.
Discussion
The concurrent collection of RNA microarray data and
detailed PBMC cell phenotyping provided powerful
means to determine associations between different gene-
expression signatures and PBMC subpopulations. This is
Figure 2 Differentially expressed probe sets and hierarchic clustering in patients with sJIA and anemia compared with patients with
non-sJIA and anemia and hierarchic clustering of controls, patients with sJIA, and those with FHLH. (a) Gene expression of 671 probes
that are differentially expressed between 18 patients with systemic arthritis and anemia and 22 patients with other subtypes of JIA and anemia.
Genes and samples are clustered by using hierarchic clustering. Four clusters are designated with Roman numerals. (b) Gene-expression pattern
of 67 probes ("erythropoiesis signature”) among healthy controls, patients with familial HLH, systemic arthritis without MAS, and systemic arthritis
with MAS. Samples are clustered by using euclidean distances.
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Page 8 of 13based on the fact that differences in gene-expression
patterns seen in the peripheral blood are due not only
to the up- and downregulation of gene expression but
also to the over- or underrepresentation of certain cell
populations. The data presented in this study demon-
strate that specific gene-expression signatures in sJIA
are associated with the expansion of immature PBMC
subpopulations and the active disease state. Further-
more, an expansion of precursor cells and upregulation
of an erythropoiesis gene-expression signature occurred
predominantly in individuals with sJIA and anemia.
Strikingly, a discrepancy was noted with strong erythro-
poiesis-related gene expression and expansion of early
precursor cells in peripheral circulation and bone mar-
row but an absence of reticulocytosis.
The etiology and pathogenesis of sJIA are poorly
understood. The lack of specific biomarkers makes diffi-
cult the diagnosis and differentiation from other febrile
conditions, and, therefore, the development of new diag-
nostic tests is highly desirable. The availability of whole-
genome gene-expression analysis technology has allowed
the discovery of sJIA-specific gene-expression signatures,
opening a window into disease pathogenesis and diagno-
sis [14,21,22].
In a previous study of sJIA, we demonstrated strong
PBMC gene-expression signatures that allowed the dis-
tinction between patients with new-onset sJIA and
healthy controls [14]. Although several signatures were
apparent, the most robust gene-expression signature was
an overexpressed 67-probe-set erythropoiesis signature
consisting of a large number of strongly erythropoiesis-
related mRNAs. “Erythropoiesis” gene-expression signa-
tures have been reported by others (for example, by
transcriptional profiling during in vitro lineage-specific
differentiation of bone marrow-derived CD34
+ precursor
cells) [23]. In addition, the reticulocyte transcriptome
derived from human umbilical cord blood reticulocytes
and adult reticulocytes contains many of the genes
described in our erythropoiesis signature [24]. In the
context of disease and in the peripheral blood, however,
reports of erythropoiesis-specific gene-expression signa-
tures have been scarce. The underexpression of erythro-
poiesis-specific signatures has been reported
predominantly [25,26]. Chua et al. [25] demonstrated
underexpression of an 11-gene erythropoiesis cluster in
anemia of chronic renal allograft rejection [25]; of these
11 underexpressed genes, four are found overexpressed
within our 67-gene erythropoiesis signature. Ebert et al.
[26] demonstrated underexpression of a 47-gene ery-
thropoiesis signature in patients with lenalidomide-
responsive myelodysplastic syndrome; of those 47
underexpressed genes, 16 are found overexpressed
within our 67-gene erythropoiesis signature. Therefore,
the presence of a “negative” gene-expression signature
Figure 3 Erythropoiesis signature in a published cohort of
healthy controls, and in patients with sJIA, bacterial infections,
PAPA syndrome, and SLE. Gene-expression data published by
Allantaz et al. [21] were retrieved from the Gene Expression
Omnibus (GEO) database. Forty-nine probe sets were identical
between the Affymetrix U133A (used by Allantaz et al.) and the
U133 Plus 2.0 arrays (used by our group) and part of the
erythropoiesis signature. The geometric mean of the linear
expression values of these 49 probe sets was calculated for the
individual samples, and the mean for the corresponding groups was
calculated. (a) Comparison of the mean of the modified
erythropoiesis indices according to the disease. (b) The mean of the
modified erythropoiesis indices comparing sJIA with or without
fever and with or without arthritis. (c) The mean of the modified
erythropoiesis indices comparing patients with sJIA receiving or not
receiving steroids, methotrexate, or infliximab. (d) Comparing the
mean of the modified erythropoiesis indices according to disease,
subdividing patients with sJIA into those with and those without
fever. Horizontal bars indicate P < 0.05 (if comparing only two
groups with Student’s t test; if comparing more than two groups,
ANOVA and post hoc Tukey testing).
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Page 9 of 13in the disease state indicates that the corresponding
genes likely are expressed in the healthy state. To our
knowledge, overexpression or upregulation of a similar
signature was not reported in the literature before our
initial description. Notably, in gene-expression studies of
sickle cell anemia, which is characterized by severe
hemolysis and subsequent expanded erythropoiesis, little
to no overlap is found with our gene-expression signa-
ture [27].
Our data suggest that the origin of the erythropoiesis-
related gene-expression signature may lie within imma-
ture and precursor cell subpopulations, most likely
CD71
+, based on the overlap of the signature with the
gene-expression pattern observed in isolated CD71
+
cells. One flaw of our study is that the study was not
designed ap r i o r ito investigate erythrocyte precursors
directly (by flow cytometry) and that some observations
were made a posteriori. Therefore, more-detailed pheno-
typing of erythrocyte precursors should be considered in
future studies to prove the suggested link. Another
strong signature, the “innate immune response cluster,”
also correlated strongly with the immature cell popula-
tions, suggesting that theym a yh a v eac e n t r a lr o l ei n
t h ep a t h o g e n e s i so fs J I A .T h ee x p a n s i o no ft h e s ec e l l
populations and upregulation of the erythropoiesis-
related signature was found most prominently in
patients with sJIA and anemia, and it was not seen in
patients with other types of JIA and anemia. The signa-
ture therefore appears to be a characteristic feature of
patients with sJIA. Replication in an independent cohort
is the gold standard to validate findings. Our data were
confirmed by a non-overlapping cohort previously pub-
lished by Allantaz et al. [21] that included patients with
other febrile diseases such as bacterial infections, SLE,
and PAPA syndrome. The analysis suggests that the ery-
thropoiesis signature is rather specific for the presence
of active sJIA (fever present), whereas it was not present
in patients with inactive sJIA (no fever and no arthritis).
Of note, a significant number of patients with bacterial
infections also overexpressed the erythropoiesis signa-
ture, pointing toward a common pathogenic mechanism
responsible for the occurrence of the signature.
An important discrepancy with strong erythropoiesis-
related gene expression and expansion of precursor cells
is found in the context of severe anemia, but conversely,
Figure 4 Pearson correlation coefficients of the “erythropoiesis
index” (geometric mean of the linear expression values of the
67 probes in the erythropoiesis signature) and several cytokine
protein levels. The “erythropoiesis index” was correlated with
cytokine protein levels across all available samples. A correlation
coefficient > 0.5 represents a large degree of correlation; a
coefficient between 0.5 and 0.3 represents moderate correlation; a
coefficient between 0.3 and 0.1 shows a small degree of correlation;
and correlation < 0.1 represents a lack of correlation. (Open bar)
Correlation across all samples, 16 normal controls, 24 enthesitis-
related, six oligo, eight poly RF-, and eight systemic JIA. (Closed bar)
Correlation in systemic JIA.
Figure 5 Bone marrow biopsy from a patient with new-onset
systemic JIA. (a) H&E staining showing hypercellular bone marrow
with prominent accumulations of nucleated erythroblasts (arrows).
(b) Immunostaining with monoclonal antibodies specific for CD163.
Brown staining identifies CD163
+ cells (some are hemophagocytic).
CD163
+ macrophages are very rare in a normal bone marrow (not
shown).
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Page 10 of 13an absence of reticulocytosis, consistent with ineffective
erythropoiesis. Ineffective erythropoiesis is the conse-
quence of the premature destruction of erythrocyte pre-
cursors either within the bone marrow or shortly after
they reach the peripheral blood [28]. According to Caz-
zola et al. [16], the phenotype of the severe anemia in
sJIA is characterized by microcytosis, hypoferremia,
hyperferritinemia, normal adjusted serum erythropoietin
levels, and normal, unadjusted erythroid blast-forming
unit levels, which the authors attribute to high circulat-
ing levels of interleukin-6 (IL-6). IL-6 is markedly
increased in sJIA [29,30], and it has a prominent effect
on erythropoiesis [31] by inducing hepatic expression of
hepcidin and subsequent decreased intestinal absorption
of iron and by inducing ferritin expression in mono-
cytes/macrophages, causing iron sequestration. The
overall effect of these actions is a markedly diminished
delivery of iron to the proliferating erythrocyte precur-
sor pool. Impaired iron delivery could potentially
explain the divergence between the presence of a strong
erythropoiesis expression signature and the absence of
reticulocytosis as a “maturation block” may occur. In
addition, IL-6 has a strong stimulatory effect on other
aspects of hematopoiesis [32,33].This suggests that IL-6
may contribute to the expansion of CD34
+ cells and the
erythropoiesis signature in active sJIA. However, the
absence of strong correlation between serum levels of
IL-6 and the strength of the signature in our cohort sug-
gests that other factors contribute to the development of
this phenomenon. The presence of increased ineffective
erythropoiesis has previously been reported in patients
with adult rheumatoid arthritis and anemia [28,34,35]. It
is possible that the severe anemia observed in sJIA has
similar underlying pathogenic mechanisms, but detailed
erythrokinetic studies have not been performed in sJIA.
Another striking feature is the similarity between sJIA/
MAS, FHLH, and bacterial infection/sepsis in many
aspects, with findings of hypercytokinemia, expansion of
cytokine-driven macrophages, hemophagocytosis, and an
increase in sCD163 levels [36-38]. These similarities
suggest a pathogenetic link between these conditions
[39] and may suggest that hemophagocytosis plays an
important role in sJIA as well. This view is supported by
the fact that 30% to 50% of patients with new-onset
sJIA have evidence for subclinical hemophagocytosis
[7,8]. The close clustering of sJIA, sJIA/MAS, and FHLH
patients by using the erythropoiesis signature and the
evidence for overexpression of the erythropoiesis signa-
ture in some patients with bacterial infection further
support the hypothesis of a shared pathogenic mechan-
ism that may include hypercytokinemia, hemophagocy-
tosis, ineffective erythropoiesis, and expansion of
immature precursor cells.
Conclusions
In summary, our findings suggest that the gene-expres-
sion pattern seen in active sJIA may be reversible and
may be the result of a shared common pathway that can
also be seen in FHLH, infection, and SLE. In these con-
ditions, profound, prolonged hypercytokinemia and the
resulting hemophagocytosis may lead to ineffective ery-
thropoiesis and the expansion of immature PBMC sub-
populations. Furthermore, in the future, gene-expression
profiling of a limited set of probes such as that con-
tained in the erythropoiesis signature may be clinically
useful for diagnostic purposes and to monitor treatment
responses.
Additional material
Additional file 1: The 67 gene erythropoiesis signature. The file
contains a list of the 67 probe sets that are upregulated in patients with
sJIA when compared with healthy controls, as reported by Fall et al. [14].
Additional file 2: Clustering of gene-expression profiles from
purified cells by using the erythropoiesis signature. The file contains
a heat map showing clustering of RNA samples from purified cell
populations. Expression levels of genes related to the 67 probe sets of
the erythropoiesis signature (only the 49 that also are found on the
U133A) were used to cluster samples from purified cell populations.
Additional cell types have been included (bone marrow, whole blood,
thymus, tonsil, lymph node, and appendix). The bright band of red on
the right represents expression of genes from CD71
+ (right-most
samples), bone marrow, and CD105
+ cells. This is consistent with the
overlap of probe sets indicated in Table 4. Each column represents one
sample, with the identification of the sample at the bottom. Each row
represents the expression of one probe set, with the probe-set IDs and
gene symbols shown on the right side of the figure. Colors indicate
increased (red) or decreased (blue) expression relative to the median
(black) of all samples.
Additional file 3: Differentially expressed probe sets between
patients with sJIA with anemia and non-sJIA patients with anemia.
The file contains a list of 671 probe sets in four different clusters that
were differentially expressed when comparing patients with sJIA with
anemia and non-sJIA patients with anemia. The four clusters are
indicated in Figure 2.
Additional file 4: Receiver-operating characteristics (ROC) curve
analysis by using the erythropoiesis index in a published cohort of
patients with sJIA and other inflammatory conditions. The file
contains figures showing (a) receiver-operating characteristics (ROC)
curve analysis, comparing active sJIA (with fever) with bacterial infection
and (b) ROC curve analysis, active sJIA (with fever) versus inactive sJIA
(no fever). Gene-expression data published by Allantaz et al. [21] were
retrieved from the Gene Expression Omnibus (GEO) database. Forty-nine
probe sets were identical between the Affymetrix U133A (used by
Allantaz et al.) and the U133 Plus 2.0 arrays (used by our group) and part
of the erythropoiesis signature. The geometric mean of the linear
expression values of these 49 probe sets was calculated for the individual
samples, and the mean for the corresponding groups was calculated.
AUC, area under the curve.
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